---

Emerging paradigms in pre-clinical screening models for drugs acting against diabetes: Delving into complex approaches and advancements

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Yash Dhamsaniya, Keval Raval*

Volume : 10, Issue : 2, Year : 2023

Article Page : 79-83

https://doi.org/10.18231/j.ijpca.2023.016

Suggest article by email

Get Permission

Abstract

Animal models play a critical role in diabetes research, aiding in the comprehension of both type 1 and type 2 diabetes pathogenesis and the assessment of potential therapeutic interventions. These models offer numerous advantages, including the ability to induce stable hyperglycemia and hyperlipidemia, minimal variability, and the opportunity to study genetic mutations and single gene effects. However, they also present limitations such as lengthy induction periods, fluctuating glucose parameters, potential toxicity to other organs, and high costs. Various screening models, encompassing in vitro assays and models like Alloxan-induced and Streptozotocin-induced diabetes, serve as valuable tools for investigating diabetes and testing drug efficacy. The selection of an appropriate model requires careful consideration of specific research objectives. Despite their limitations, animal models continue to be indispensable for advancing our understanding of diabetes and developing effective treatments.

Keywords: Glibenclamide, hyperglycemia, Streptozotocin (STZ)

How to cite : Dhamsaniya Y, Raval K, Emerging paradigms in pre-clinical screening models for drugs acting against diabetes: Delving into complex approaches and advancements. Int J Pharm Chem Anal 2023;10(2):79-83

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.